Strategic partnerships Aridis has a history of collaboration with notable organizations (IAVI, Gates Foundation, AstraZeneca) and license deals, indicating openness to partnership models and potential for co-development or in-licensing arrangements to expand product reach.

Inhaled delivery niche The company emphasizes advanced inhaled formulations for monoclonal antibodies and infectious disease agents, signaling opportunities to sell specialized formulation services or platform licensing to large biotechs seeking efficient pulmonary delivery solutions.

Focused infectious diseases With a portfolio centered on HIV vaccine candidates, AMR/CF-related therapies, and broader infectious disease programs, there is potential to position Aridis as a source of novel antibodies or adjuvanted vaccine platforms for partner programs targeting high-need pathogens.

Funding momentum Active external funding from Gates Foundation and CF Foundation demonstrates validation and appetite for funded collaborations, suggesting sales tactiques could leverage co-funding, milestone-driven partnerships, and grant-aligned programs.

Early-stage scale Small team size (2-10 employees) and revenue in the low to mid single digits imply a focus on strategic, high-impact deals with larger partners where credibility is reinforced through existing alliances and demonstrated technology readiness rather than broad commercial scale.